Best GLP-1 for Active Military and Veterans (2026 TRICARE, VA, and Cash-Pay Guide)

Overview

The best GLP-1 for active military and veterans depends on one thing: your status. There is no single winner. If you are active duty or have TRICARE Prime or Select, your fastest path is your PCM or a TRICARE-authorized provider — and the 2026 copay is $0 for active duty, $44 for a 90-day brand-name supply through TRICARE Home Delivery for everyone else. Initial PA approval is for 12 months, with annual renewal. If you are a veteran enrolled in VA care, semaglutide through MOVE! is typically the strongest path. For TRICARE For Life beneficiaries, weight-loss GLP-1 coverage ended August 31, 2025 — cash-pay or manufacturer direct-pay is now the path. CHAMPVA does not cover GLP-1s for weight loss alone in 2026.

Here is the part most pages will not tell you: cash-pay telehealth is faster, but for active duty it is not always safer. Your medication has to be in your military health record. Some operational platforms and special-duty assignments restrict GLP-1 use. Compounded GLP-1s are not on the FAA’s list for aviators. We will show you when to use the official path, when to use cash-pay, and when to slow down and talk to your medical officer first.

What is the best GLP-1 for active military and veterans?

For most TRICARE Prime, Select, Reserve Select, Retired Reserve, US Family Health Plan, Young Adult, and Continued Health Care Benefit Program (CHCBP) beneficiaries, the best GLP-1 in 2026 is whichever brand-name FDA-approved option (Wegovy, Zepbound, or Saxenda) your network provider documents as medically necessary in the TRICARE prior authorization. For veterans enrolled in VA care, semaglutide through MOVE! is typically the strongest path. For TRICARE For Life beneficiaries who lost weight-loss GLP-1 coverage on August 31, 2025, and for CHAMPVA beneficiaries without a qualifying diagnosis, the best path is FDA-approved branded medication through a transparent cash-pay telehealth provider that matches manufacturer direct-pay pricing.

What we actually verified for this guide

We are an independent comparison resource for GLP-1 telehealth providers. This page is built from primary sources, not provider marketing.

• TRICARE 2026 pharmacy copays (Express Scripts, effective Jan 1, 2026)
• TRICARE Wegovy and Zepbound prior authorization form (Express Scripts, current as of January 2026): 12-month initial approval, annual renewal, sympathomimetic anorexiant step-therapy requirement
• TRICARE plan eligibility (TRICARE.mil FAQ on Wegovy, Ozempic, and Mounjaro coverage)
• TRICARE For Life weight-loss medication coverage termination (Defense Health Agency, effective Aug 31, 2025)
• CY2026 TRICARE Plan Program Changes (Federal Register, Oct 28, 2025)
• VA outpatient medication copay rates 2026 (VA.gov)
• VA Wegovy non-formulary criteria for use (VA Pharmacy Benefits Management Services)
• CHAMPVA covered conditions (last VA update April 2026)
• DoD waist-to-height ratio standard (Dec 18, 2025 memo from the Office of the Under Secretary of Defense for Personnel and Readiness; effective Jan 1, 2026)
• Marine Corps WHtR standard (MARADMIN 066/26, released Feb 26, 2026, effective Jan 1, 2026)
• FAA Weight Loss Pharmaceutical worksheet (updated Aug 27, 2025) and CACI Weight Loss Management Worksheet
• OPSS (Operation Supplement Safety) guidance on semaglutide for service members
• Foundayo (orforglipron) FDA approval (April 1, 2026)
• FDA enforcement against compounded GLP-1 marketers (March 3, 2026 announcement: 30 telehealth companies warned)
• FDA April 2026 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list
• Ro, Sesame Care, and Eden published pricing, current as of verification date

Anything that could change quickly — pricing, formulary status, branch-specific implementation — has the verification date attached. If you are reading this more than 90 days after the date above, double-check the linked source before you act on a number.

Quick verdict by status

This is the original Military and Veteran GLP-1 Path Matrix. Find your row.

Real questions we built this page to answer

We are not making these up. These are the questions service members and veterans are actually typing — pulled from public Reddit and veteran forum threads:

If any of those sound familiar, you are in the right place. We are going to answer all three.

Can active-duty military take a GLP-1?

Short answer: Yes. GLP-1 medications are prescription drugs obtained through normal medical channels. They are not controlled substances. You must disclose all prescribed medications to your unit medical authority. Use during training, deployments, or operational platforms may be restricted on a case-by-case basis. Operation Supplement Safety (OPSS) guidance is direct: discuss operational, training, and deployment impacts with a DoD medical officer before starting semaglutide.

That answer covers most active-duty readers. Now the details that matter for the rest.

Will GLP-1 use affect my security clearance or urinalysis?

Prescription GLP-1 use through normal medical channels is not the same as illegal drug use or prescription-drug misuse. Clearance risk comes from misuse, unverified sellers, false statements, or hiding required medical information — not from properly prescribed obesity or diabetes treatment. The medication will appear in your military health record but is not the kind of thing flagged on routine reviews of properly prescribed prescriptions.

On urinalysis: DoD drug testing screens for the substances on the authorized DoD drug-testing panel. Semaglutide and tirzepatide are not part of that standard controlled-substance panel. The bigger issue with GLP-1s is documentation — make sure the prescription is in your military health record and you have disclosed it to your unit medical authority. If you have specific questions about your testing program, ask your unit medical officer.

What does cause clearance and career trouble: buying “research use only” peptides, ordering from unverified offshore sellers, or hiding the medication from military medical care. Avoid all three.

Will it show up in my military health record?

Yes. Anything filled through TRICARE Home Delivery, an MTF pharmacy, or a TRICARE network retail pharmacy is documented. Your command does not routinely review your prescription list. Your unit medical authority, flight surgeon, dive medical officer, and special-duty medical officers can.

If you fill cash-pay outside the TRICARE network, you are still required to disclose the medication to your unit medical authority. OPSS specifically advises that civilian providers treating service members should understand TRICARE coverage and operational considerations, and that all medications belong in the military health record.

Will it make me non-deployable?

Not automatically. Active medical treatment plans get periodic review, and that review can affect deployability if the medication or condition is unstable. The two real considerations:

1. Side effects during dose titration. Nausea, GI distress, and fatigue are common during the first 4 to 8 weeks. Time the start carefully if you have a fitness test, deployment workup, or high-tempo period coming up.
2. Cold-chain logistics. Wegovy and Zepbound pens require refrigeration before first use. After first use, Wegovy pens can sit at room temperature for up to 28 days; Zepbound pens for 21 days. Plan medication management with your unit surgeon if deployment is in the cycle.

OPSS is explicit: discuss operational, training, and deployment impacts with a DoD medical officer before starting semaglutide. That is the move that protects your career if anything goes sideways later.

What about the new waist-to-height ratio standard?

A December 18, 2025 memo from the Office of the Under Secretary of Defense for Personnel and Readiness directed the Military Departments to use the waist-to-height ratio (WHtR) as the body-composition measurement beginning January 1, 2026. Height-and-weight tables are no longer used to evaluate body composition. Your waist measurement divided by your height — same units — must come in below your service’s threshold.

Where each branch lands:

• Marine Corps: WHtR less than or equal to 0.52 (per MARADMIN 066/26, released Feb 26, 2026, effective Jan 1, 2026)
• Navy: WHtR at or below 0.55 (Physical Readiness Program guidance, December 2025)
• Air Force / Space Force: WHtR at or below 0.55
• Army: Army Fitness Test score of 465+ with 80+ in each event earns a body-fat exemption; otherwise the WHtR screen applies under DoD guidance

What this means in practice: published clinical-trial data on semaglutide and tirzepatide shows roughly 10% to 20% average body weight loss over 6 to 12 months. Whether that is enough to get you back inside your service’s WHtR threshold depends on your starting point. Use a WHtR calculator with your height and current waist before starting medication so you know the actual inches you need to lose — clinical-trial averages do not guarantee compliance for any specific person.

Does the VA prescribe GLP-1 medications for veterans?

Short answer: Yes. The VA prescribes semaglutide (Wegovy) for veteran weight loss as a non-formulary medication that requires criteria-for-use approval submitted by your VA prescriber. Veterans typically need a BMI of 30 or higher, OR a BMI of 27 or higher with a weight-related condition, plus engagement in the MOVE! Weight Management Program. Some veterans pay $0 because they are exempt; for non-exempt veterans, 2026 VA outpatient medication copays are tiered, with Tier 3 brand-name prescriptions at $11 for 1–30 days, $22 for 31–60 days, and $33 for 61–90 days, capped at $700 per calendar year. Approval timelines vary by VA medical center.

What the VA covers for veterans

• Semaglutide injection (Wegovy) — non-formulary, criteria-for-use applies
• Tirzepatide (Zepbound) — verify current VA formulary status; many facilities treat it as non-formulary and may route veterans to semaglutide first
• Liraglutide (Saxenda) — non-formulary in most cases
• Ozempic, Mounjaro, Trulicity, Victoza — covered for type 2 diabetes (formulary varies by facility)

VA Wegovy criteria-for-use checklist

Bring this to your VA primary care appointment:

• BMI of 30 or higher, OR BMI of 27 or higher with at least one weight-related condition (high blood pressure, MASLD, prior heart attack or stroke, type 2 diabetes, high cholesterol, osteoarthritis, obstructive sleep apnea)
• Documented enrollment in or completion of MOVE! or another approved comprehensive lifestyle intervention
• Trial of at least one prior weight-loss intervention (lifestyle counseling alone may count at some facilities; others require pharmacotherapy step therapy)
• For females of childbearing potential: negative pregnancy test, contraception counseling
• Provider willing to submit a non-formulary request with clinical justification

Do you have to go through MOVE! first?

The VA’s published guidance pairs weight-management medicines with an approved weight-management program — and MOVE! is the standard pathway. Facility timing and local workflow vary. Some VA facilities prescribe quickly after MOVE! enrollment; others want longer participation before considering pharmacotherapy. There is no national rule on this. Ask your VA PCP what your local VA requires before assuming a specific timeline.

If your facility is on the slower end, you have three real options:

1. Continue MOVE!, document your participation in detail, and re-petition.
2. Request a Community Care Network referral if you meet drive-time or wait-time eligibility standards.
3. Run a parallel cash-pay path so you have access during the wait.

What VA research actually shows about GLP-1s for veterans

These studies do not guarantee your result and should not be used as a substitute for your clinician’s judgment. They do show what has been observed in real veteran populations:

• A study at the Rocky Mountain Regional VA Medical Center tracked 201 veterans prescribed semaglutide in the facility’s weight management clinic. After one year, average body weight loss was 10%, with measurable improvements in BMI, blood pressure, LDL cholesterol, triglycerides, blood sugar, and self-reported quality of life. Published in the Journal of General Internal Medicine.
• A WashU/VA analysis of more than 600,000 U.S. veterans with type 2 diabetes found GLP-1 use was associated with lower risk of developing several substance-use disorders, and lower rates of severe harms — including suicidal thoughts or attempts — among veterans with existing substance-use disorders. This is observational association, not proof that GLP-1s treat addiction or suicide risk.
• A 37-site VA medication-use evaluation found semaglutide, phentermine/topiramate, and orlistat were among the most frequently prescribed weight-management medications, with veterans showing beneficial weight loss particularly on semaglutide, phentermine/topiramate, and liraglutide.

Those are peer-reviewed outcomes from VA clinical settings, and they are directly relevant to whether this medication will work for someone with a service-connected condition, PTSD-related medication weight gain, or chronic pain that limits exercise. Your VA provider knows them — or should. Bring them up.

CHAMPVA coverage of GLP-1 medications (April 2026 update)

Short answer: CHAMPVA does not cover GLP-1 medications for weight loss in 2026. CHAMPVA covers GLP-1 medications only when prescribed for specific FDA-approved indications: Mounjaro, Ozempic, Rybelsus, Trulicity, and Victoza for type 2 diabetes; Zepbound for obstructive sleep apnea; and Wegovy for metabolic-associated steatohepatitis (MASH) or prevention of major adverse cardiovascular events (MACE). Saxenda is not covered.

What CHAMPVA covers, by diagnosis

If you do not have a qualifying diagnosis, CHAMPVA will not cover GLP-1 medications for weight loss alone. Don’t waste time on a prior authorization for the wrong indication.

Your real options if you are CHAMPVA

1. If you have a qualifying condition, work with your provider on the matching prescription pathway (Wegovy for MACE, Zepbound for OSA, the diabetes drugs for T2D).
2. If your goal is weight loss without one of those conditions, your Plan B is a transparent cash-pay branded path (Ro is the cleanest fit) or a compounded telehealth option (lower cost, more limitations — see the compounded section below).

TRICARE For Life beneficiaries — what changed August 31, 2025

If you came here because you got the letter from Express Scripts, this section is for you. We are not going to pitch you. We are going to tell you what your real options are.

What happened: On August 31, 2025, the Defense Health Agency terminated TRICARE For Life weight-loss medication coverage. Wegovy, Zepbound, Saxenda, Contrave, Qsymia, and phentermine all lost coverage for TFL, direct-care-only beneficiaries, foreign force members, and TRICARE Plus enrollees. Existing prior authorizations became invalid that same day. TRICARE Prime, Select, Reserve Select, and other premium-based plans were not affected.

Why it happened: TFL provides secondary coverage to military retirees who have aged into Medicare. Medicare itself does not cover GLP-1 medications strictly for obesity — only for type 2 diabetes or specific cardiovascular indications. The DHA cited “alignment with federal coverage requirements” as the basis for the change. MOAA and other military service organizations are advocating for reinstatement. As of this guide’s verification date, no reversal has happened.

What is still covered for TFL: GLP-1 medications prescribed for type 2 diabetes (Ozempic, Mounjaro, Trulicity, Victoza) remain covered with prior authorization. Bariatric surgery for morbid obesity remains covered.

What that means for you: If you were on Wegovy or Zepbound through TFL, you can keep taking the medication only by paying out of pocket. TFL will not reimburse it. Stopping abruptly typically leads to weight regain — talk to your provider before discontinuing.

Your three real options as a TFL beneficiary in 2026

Option 1: Wait for legislative or regulatory change. MOAA is pushing hard. Don’t rely on this if you need access now.

Option 2: Pay out of pocket through manufacturer programs. LillyDirect (for Zepbound) and NovoCare (for Wegovy) offer manufacturer direct-pay pricing. Verify current prices on those programs. Standard retail pricing without insurance runs $900 to $1,400 per month.

Option 3: Transparent cash-pay through telehealth. Ro now matches LillyDirect, NovoCare, and TrumpRx pricing on FDA-approved branded medication. They carry Wegovy pen, Wegovy pill, Zepbound pen, Zepbound KwikPen, and Foundayo (orforglipron, FDA-approved April 1, 2026). They include a free GLP-1 Insurance Coverage Checker — useful if your situation changes back. They have an insurance concierge for FEHB and other commercial plans (not TRICARE). Ro Body membership is $39 for the first month, then $149/month, or as low as $74/month with annual prepay, with medication billed separately at LillyDirect-matching prices.

Guard, Reserve, and TRICARE Reserve Select

Short answer: National Guard and Reserve members on Title 10 active duty orders for more than 30 consecutive days have full TRICARE Prime coverage, including weight-loss GLP-1s with PA. Reservists not on active orders typically use TRICARE Reserve Select (TRS), which follows the same coverage rules and copay structure. TRICARE Retired Reserve has similar pathways with plan-specific premiums.

TRS is a premium-based health plan available to most members of the Selected Reserve. As a premium-based plan, TRS follows the standard TRICARE rules for weight-loss GLP-1s — Wegovy, Zepbound, and Saxenda are covered with PA. Pharmacy copays follow the 2026 schedule: $14 for a 90-day generic, $44 for a 90-day brand-name, $85 for non-formulary at Home Delivery.

A few things specific to Guard/Reserve:

• Orders changes affect access. If you go on or off active orders mid-treatment, your coverage and copays may shift. Verify your DEERS status and coordinate with Express Scripts.
• Drilling status doesn’t dictate the PA timeline. A network civilian provider works fine for the PA — you don’t have to wait until a drill weekend.
• State activation under Title 32 typically does not provide TRICARE coverage. State-specific medical benefits may apply during state active duty.

Military pilots and aviators — the flight status reality

This section matters specifically for military aviators, civilian pilots holding an FAA medical, and anyone in a special-duty role with aeromedical oversight.

Short answer: The FAA Weight Loss Medication table lists GLP-1 agonists — including liraglutide, semaglutide (Wegovy), and tirzepatide (Zepbound) — as acceptable for pilots holding medical certification when certification criteria are met. The CACI Weight Loss Management Worksheet specifies a 2-week observation period after starting the medication and 72-hour observation with each dosage change. FAA materials reviewed list FDA-approved brand-name GLP-1 medications in the acceptable table; they do not list compounded GLP-1s. For flight status, do not use compounded GLP-1s unless your AME or flight surgeon explicitly clears and documents it.

What the FAA permits, and the criteria

Acceptable single-medication GLP-1 use for pilots holding medical certification (with criteria):

• Semaglutide — Wegovy (and Ozempic when used for diabetes under separate diabetes criteria)
• Tirzepatide — Zepbound
• Liraglutide — Saxenda

Conditionally acceptable (typically requires Special Issuance):

• Combinations of two diabetic medications (for example, metformin plus a GLP-1 agonist used together)

Not in the FAA’s acceptable list:

• Compounded semaglutide
• Compounded tirzepatide

The required criteria, per the FAA Weight Loss Pharmaceutical worksheet (updated August 27, 2025):

• Hemoglobin A1C consistently below 6.5% (no current diabetes diagnosis)
• 2-week observation period after starting the medication for weight loss
• 72-hour observation with each dosage change, either increasing or tapering
• No impairing side effects: nausea, dizziness, fatigue, mood changes
• Documentation from the treating physician confirming clinical stability and absence of side effects
• AME review using the FAA CACI Weight Loss Management Worksheet
• Annual re-evaluation as part of medical certification renewal

(Always follow the current AME Guide — FAA worksheet language updates and your AME has the controlling reference for your physical.)

Why this matters specifically for military aviators

Military aviators are subject to service-specific aeromedical authority (Air Force, Navy, Marine Corps, Army aviation flight surgeons). Service flight surgeons generally reference FAA guidance for newer weight-loss medications but apply branch-specific waivers and operational-platform considerations.

The two non-negotiable rules across services:

1. Disclose GLP-1 use to your flight surgeon. Unauthorized use risks loss of flight status — permanently. The medication itself isn’t the career risk. Hiding it is.
2. FAA materials don’t list compounded GLP-1s as acceptable. Even when not explicitly prohibited by your service, compounded formulations are not on the FAA’s acceptable list, are not FDA-approved as finished products, and create a documentation problem you don’t need.

If you fly — military or civilian — your cleanest GLP-1 path is FDA-approved branded medication, prescribed and documented through a provider who understands the AME workflow.

Cash-pay GLP-1 options for military and veterans (when the system path won’t work)

When TRICARE, the VA, or CHAMPVA won’t cover what you need — or the timeline is unworkable — here are the cash-pay options that actually fit a military or veteran reader, ranked by audience fit, not by what pays us the most.

The decision: FDA-approved branded vs. compounded

This is the fork in the road.

FDA-approved branded (Wegovy, Zepbound, Foundayo, Saxenda) is the cleanest path for:

• Aviators and anyone holding a flight medical
• Active duty in regulated occupations
• Anyone who plans to use TRICARE or the VA later
• Anyone uncomfortable with the regulatory uncertainty around compounded GLP-1s

Compounded (semaglutide and tirzepatide produced by 503A or 503B compounding pharmacies — the federal categories that allow pharmacies to mix custom medications) may be available in limited patient-specific circumstances when federal and state compounding requirements are met. But they are not FDA-approved finished products, and the FDA cannot verify their quality, safety, or effectiveness.

A few things that aren’t negotiable. Compounded GLP-1s are not the same as FDA-approved Wegovy, Zepbound, Ozempic, or Mounjaro. The FDA has been explicit on this. On March 3, 2026, the FDA announced warning letters to 30 telehealth companies for false or misleading marketing claims about compounded GLP-1s. In April 2026, the FDA proposed to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list after determining there was no clinical need for outsourcing facilities to compound drugs using those bulk substances. Any provider that tells you compounded is “the same active ingredient” as a branded medication, or “clinically proven” to produce the same results, is using language the FDA has called false or misleading. Walk away.

Why we left some providers off the lead recommendations

We are an independent comparison resource for GLP-1 telehealth providers. We earn affiliate commissions when readers sign up through our links. We don’t accept payment for placement, and our rankings reflect verified evidence and audience fit — not commission rates.

For this page specifically — military and veteran readers — here is what we left off the lead recommendations and why:

• MEDVi: On February 20, 2026, the FDA issued warning letter #721455 to MEDVi, citing misbranding violations and language that falsely implied FDA approval of compounded products and that MEDVi was the compounder. The FDA letter specifically called out “Same active ingredient as Wegovy and Ozempic” and “Same active ingredient as Mounjaro and Zepbound” claims. MEDVi was one of 30 telehealth companies warned in this enforcement wave. Warning letters are advisory, not findings of guilt — but for a YMYL military and veteran audience, we are not comfortable leading with a provider under active FDA scrutiny until remediation is fully verified.
• Hims and Hers: Following Hims & Hers’ announced strategic shift toward FDA-approved Novo Nordisk GLP-1s, both now offer FDA-approved options. They are legitimate. They didn’t make the lead recommendation here because Ro and Sesame currently offer broader branded formulary with stronger insurance support for this audience. Hims previously announced a 2024 service-appreciation initiative offering compounded GLP-1s as low as $99/month for U.S. military, veterans, teachers, nurses, and first responders — verify current military and veteran pricing terms directly with Hims since their formulary has shifted.
• SHED, Yucca, Direct Meds, and other compounded providers: These are legitimate compounded cash-pay options for the right reader, but the right reader for this page is overwhelmingly someone who needs FDA-approved branded medication or who wants a clean compounded option with strong disclosure language. Eden serves that fallback well for this audience.

This is the part most affiliate pages won’t tell you: there is real money in recommending the highest-paying provider for every page. We don’t do that here. If we recommend the wrong provider for an aviator or a regulated-occupation service member, the consequences for the reader are real. We pick the provider that fits.

Compounded GLP-1 safety — what military and veteran readers should know

If you are considering compounded GLP-1s, here is what is actually true.

Short answer: Compounded semaglutide and compounded tirzepatide are produced by compounding pharmacies under sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act. They are not FDA-approved as finished products. They have not gone through the same clinical trial process as Wegovy, Zepbound, Ozempic, or Mounjaro. The FDA has flagged dosing errors, illegal sellers, counterfeit products, and “research use only” peptides as ongoing safety concerns, and on March 3, 2026 issued warning letters to 30 telehealth companies for false or misleading compounded GLP-1 marketing. Compounded GLP-1s may be available in limited patient-specific circumstances when compounding requirements are met; they are not appropriate for aviators or anyone in a role requiring FDA-approved medication.

When compounded might fit your situation

• You are not using TRICARE, VA, or CHAMPVA coverage for this prescription
• You understand compounded products are not FDA-approved
• A licensed clinician — actually licensed, not “research use only” — evaluates you
• The pharmacy is licensed and named (a real 503A or 503B pharmacy, not anonymous)
• Pricing, cancellation terms, dosing instructions, and clinical support are clear before payment
• You disclose medication use to relevant care teams, including military medical authority

When compounded is the wrong move

• You are an active-duty service member with deployment, training, or operational platform concerns
• You need insurance or PA support
• You hold or plan to hold an FAA medical certificate
• You want FDA-approved branded medication
• The provider claims “same active ingredient as Wegovy” or “clinically proven” results
• The provider hides the pharmacy source, the prescribing clinician, or the cancellation terms

FDA red flags — what to avoid completely

• “Research use only” or “not for human consumption” peptide sellers
• No licensed prescriber
• No licensed pharmacy
• No real medical evaluation
• Spelling or address errors on labels
• Claims that compounded products are “generic versions” of FDA-approved brands
• “Same active ingredient” or “clinically proven” claims for compounded versions

The FDA’s position in 2026 is clear: marketing language cannot claim compounded products are equivalent to or the same as FDA-approved drugs. If a provider is using that language, they are using language the FDA has already cited as false or misleading.

Honest tradeoffs — what GLP-1s actually do, and what they don’t

Short answer: GLP-1 medications are powerful and effective for clinical weight loss, but they come with tradeoffs that matter specifically to military and veteran readers. Common side effects include nausea, vomiting, constipation, and fatigue, particularly during the first 4 to 8 weeks of dose titration. Published clinical-trial body-composition data shows a meaningful share of weight lost on semaglutide and tirzepatide is lean tissue, which matters for combat-arms personnel and special-duty service members. The medication is not a one-time fix — discontinuation typically leads to weight regain. Coverage rules and pricing change frequently.

The negatives, stated plainly

Side effects during titration are real. Nausea, GI distress, and fatigue can affect performance during the first 4 to 8 weeks. Plan around fitness tests, deployment workups, school dates, and high-tempo periods.

Lean mass loss matters for combat arms and special duty. Published clinical-trial body-composition data shows a meaningful proportion of weight lost on semaglutide and tirzepatide is lean tissue. Resistance training and clinician-guided nutrition planning can help reduce that risk. If you depend on absolute strength for your MOS, account for this with your provider.

You will likely need to continue the medication indefinitely. Discontinuation leads to weight regain in the majority of patients. Plan for this as a long-term medical commitment.

Cold-chain logistics for deployment. Wegovy and Zepbound pens require refrigeration before first use. Plan medication management with your unit surgeon if deployment is in the cycle.

Compounded is not branded. If anyone tells you compounded semaglutide is “the same as Ozempic” or “clinically proven” — they are using language the FDA has called false or misleading. Compounded GLP-1s are not FDA-approved. They are not appropriate for aviators or anyone in a regulated occupation.

Pricing changes. TRICARE copays adjust on the FY18 NDAA cycle. VA formulary status shifts. Manufacturer direct-pay pricing changes. Verify current numbers before relying on a price quoted in any guide — including this one.

Who should not use a GLP-1

The FDA prescribing labels for semaglutide and tirzepatide list formal contraindications including personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and serious hypersensitivity to the medication. Pregnancy or planned pregnancy, history or symptoms of pancreatitis, and severe gastrointestinal disease (including severe gastroparesis) are clinician-screening or warning issues that may also rule out treatment. Discuss your full medical history with your prescriber. The FDA prescribing information for each medication has the complete list.

Frequently asked questions

Real outcomes from real veterans

These studies do not guarantee your result and should not be used as a substitute for your clinician’s judgment. Here is what published VA-funded research has actually found in veteran populations on GLP-1 medications:

• The Rocky Mountain Regional VA Medical Center weight management clinic study tracked 201 veterans on semaglutide for one year. Average body weight loss was 10%, with measurable improvements in BMI, blood pressure, LDL cholesterol, triglycerides, blood sugar, and self-reported quality of life. Published in the Journal of General Internal Medicine.
• A WashU/VA analysis of more than 600,000 U.S. veterans with type 2 diabetes found GLP-1 use was associated with lower risk of developing several substance-use disorders, and lower rates of severe harms — including suicidal thoughts or attempts — among veterans with existing substance-use disorders. This is observational association, not proof that GLP-1s treat addiction or suicide risk.
• A 37-site VA medication-use evaluation found semaglutide, phentermine/topiramate, and orlistat were among the most frequently prescribed weight-management medications, with veterans showing beneficial weight loss particularly on semaglutide, phentermine/topiramate, and liraglutide.

Those aren’t marketing numbers. They are peer-reviewed outcomes from VA clinical settings, directly relevant to whether this medication will work for someone with a service-connected condition, PTSD-related medication weight gain, or chronic pain that limits exercise.

How we built this guide

Weight Loss Provider Guide is an independent comparison resource for GLP-1 telehealth providers. We are not a medical practice. We don’t sell medication. We compare options for readers and route them to the path that fits their situation.

For this guide specifically, we verified every numeric and policy claim against:

• TRICARE.mil and Express Scripts pharmacy program documents (including the current Wegovy and Zepbound prior authorization request form)
• The Federal Register CY2026 TRICARE Plan Program Changes notice (October 28, 2025)
• VA Pharmacy Benefits Management Services criteria-for-use documents and the VA Formulary Advisor
• VA.gov copay rates for 2026 and CHAMPVA covered medications guidance (April 2026 update)
• The Defense Health Agency’s August 2025 announcements on TFL coverage and the September 2025 Q&A
• The December 18, 2025 memo from the Office of the Under Secretary of Defense for Personnel and Readiness on body composition standards
• MARADMIN 066/26 (Marine Corps body composition standards, effective Jan 1, 2026)
• The FAA’s Weight Loss Pharmaceutical worksheet (updated August 27, 2025) and CACI Weight Loss Management Worksheet
• Operation Supplement Safety (OPSS) guidance on semaglutide for service members
• FDA prescribing information for Wegovy, Zepbound, Ozempic, Mounjaro, Foundayo, and Saxenda
• FDA enforcement announcements: March 3, 2026 (30 telehealth companies warned); FDA warning letter #721455 (MEDVi, Feb 20, 2026); April 2026 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list
• Published pricing pages for Ro, Sesame Care, and Eden

We earn affiliate commissions when readers sign up for the telehealth services we recommend. We don’t accept payment for placement, and we don’t reorder our rankings to chase commission rates. The provider routing on this page reflects the right fit for a military and veteran audience — including the specific decision to omit MEDVi from the lead recommendations because of the active FDA warning letter, even though MEDVi pays well.

If a number on this page is older than 90 days, click through to the source we cited to verify it before you act on it. We re-verify quarterly.

Last verified: May 2, 2026
Next scheduled re-verification: August 1, 2026

Find your military or veteran GLP-1 path in 60 seconds

If everything above gave you the answer you needed, run with it. If you are still not sure which row of the matrix is yours, we built a 60-second quiz that asks for your status, your situation, and what matters most to you, and routes you to the exact next step. No email required. No upsell. Just the answer.

Related guides on Weight Loss Provider Guide

• Highest-rated GLP-1 telehealth providers (general)
• Best cash-pay GLP-1 for seniors on Medicare
• Best GLP-1 for self-employed and 1099 workers
• Cheapest FDA-approved GLP-1
• Best Foundayo (orforglipron) providers
• Best online Wegovy providers
• Best online Zepbound providers
• Providers that handle prior authorization for you
• Best compounded semaglutide providers
• Cheapest GLP-1 without insurance

Sources and verification

• TRICARE.mil official FAQ on Wegovy, Ozempic, and Mounjaro coverage
• Express Scripts TRICARE Wegovy and Zepbound prior authorization request form (current as of January 2026)
• TRICARE 2026 pharmacy copay schedule (Express Scripts, effective Jan 1, 2026)
• Defense Health Agency announcements on TRICARE For Life weight-loss medication coverage termination (effective Aug 31, 2025) and September 2025 Q&A
• Federal Register, CY2026 TRICARE Plan Program Changes (published October 28, 2025)
• VA Pharmacy Benefits Management Services Wegovy criteria-for-use document
• VA.gov outpatient medication copay rates for 2026; CHAMPVA covered medications guidance (April 2026 update)
• December 18, 2025 memo from the Office of the Under Secretary of Defense for Personnel and Readiness on waist-to-height ratio body composition standards (effective Jan 1, 2026)
• MARADMIN 066/26 (Marine Corps body composition standards, released Feb 26, 2026)
• FAA Weight Loss Pharmaceutical worksheet (updated August 27, 2025) and CACI Weight Loss Management Worksheet
• Operation Supplement Safety (OPSS) guidance on semaglutide for service members
• FDA prescribing information for Wegovy, Zepbound, Ozempic, Mounjaro, Foundayo, and Saxenda
• FDA news release on Foundayo (orforglipron) approval (April 1, 2026)
• FDA enforcement: March 3, 2026 announcement (30 telehealth companies warned); FDA warning letter #721455 (MEDVi, February 20, 2026); April 2026 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list
• Rocky Mountain Regional VA Medical Center weight management clinic study (Journal of General Internal Medicine)
• WashU/VA analysis of GLP-1 use in U.S. veterans with type 2 diabetes
• 37-site VA medication-use evaluation of weight-management medications
• Ro official Weight Loss Program, GLP-1 Insurance Coverage Checker, and Zepbound KwikPen pages
• Sesame Care official online weight-loss program pricing
• Eden official treatment, pricing, and FSA/HSA pages
• NovoCare Pharmacy and LillyDirect official self-pay pricing pages
• Centers for Medicare & Medicaid Services (CMS) Medicare GLP-1 Bridge program guidance

Pricing, policies, and regulatory information were verified May 1–2, 2026. We re-verify monthly and update this page on a quarterly schedule, with hard refresh dates calendared to manufacturer promo expirations and FDA policy changes. Please re-check provider pages directly before purchasing — pricing can shift without notice.